Lupus eritematoso sistémico

1. Sirobhushanam S, Lazar S, Kahlenberg JM. 2021. Interferons in systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 47:297–315

2. Arbuckle MR, McClain MT, Rubertone MV, et al. 2003. Development of autoantibodies before the clinical onset of systemic lupus erythematosus.N. Engl. J. Med. 349:1526–33

3. Rees F, Doherty M, Lanyon P, et al. 2017. Early clinical features in systemic lupus erythematosus: Can they be used to achieve earlier diagnosis? A risk prediction model. Arthritis Care Res. 69:833–41

4. Drenkard C, Lim SS. 2019. Update on lupus epidemiology: advancing health disparities research through the study of minority populations. Curr. Opin. Rheumatol. 31:689–96

5. Chan EK,Damoiseaux J, deMeloCruvinelW, et al. 2016. Report on the second InternationalConsensus on ANA Pattern (ICAP) workshop in Dresden 2015. Lupus 25:797–804

6. Pisetsky DS. 2017. Antinuclear antibody testing—misunderstood or misbegotten? Nat. Rev. Rheumatol. 13:495–502

7. Agmon-Levin N, Damoiseaux J, Kallenberg C, et al. 2014. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann. Rheum. Dis. 73:17–23

8. Satoh M, Chan EK, Ho LA, et al. 2012. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum. 64:2319–27

9. Abeles AM, AbelesM. 2013. The clinical utility of a positive antinuclear antibody test result.Am. J.Med. 126:342–48

10. Li QZ, Karp DR, Quan J, et al. 2011. Risk factors for ANA positivity in healthy persons. Arthritis Res. Ther. 13:R38

11. Mahler M, Hanly JG, Fritzler MJ. 2012. Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases. Autoimmun. Rev. 11:642–45

12. Mariz HA, Sato EI, Barbosa SH, et al. 2011. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum. 63:191–200

13. Pisetsky DS. 2016. Anti-DNA antibodies—quintessential biomarkers of SLE. Nat. Rev. Rheumatol. 12:102–10

14. Damoiseaux J, Andrade LEC,Carballo OG,et al. 2019. Clinical relevance ofHEp-2 indirect immunofluorescent patterns: the International Consensus on ANA Patterns (ICAP) perspective. Ann. Rheum. Dis. 78:879–89

15. AringerM,Costenbader K, DaikhD, et al. 2019. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 71:1400–12

16. Suda M, Kishimoto M, Ohde S, Okada M. 2020. Validation of the 2019 ACR/EULAR classification criteria of systemic lupus erythematosus in 100 Japanese patients: a real-world setting analysis. Clin. Rheumatol. 39:1823–27

17. Abdwani R, Al Masroori E, Abdullah E, et al. 2021. Evaluating the performance of ACR, SLICC and EULAR/ACR classification criteria in childhood onset systemic lupus erythematosus. Pediatr. Rheumatol. 19:141

18. AlexanderRV, ReyDS, Conklin J, et al. 2021.Amultianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus. Lupus Sci.Med. 8:e000528

19. Putterman C, Furie R, Ramsey-Goldman R, et al. 2014. Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. Lupus Sci.Med. 1:e000056

20. Hui-Yuen JS,Gartshteyn Y, Ma M, et al. 2018. Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity. Lupus 27:2262–68

21. Ramsey-Goldman R, Alexander RV, Massarotti EM, et al. 2020. Complement activation in patients with probable systemic lupus erythematosus and ability to predict progression to American College of Rheumatology-classified systemic lupus erythematosus. Arthritis Rheumatol. 72:78–88

22. Arriens C, Alexander RV, Narain S, et al. 2020. Cell-bound complement activation products associate with lupus severity in SLE. Lupus Sci.Med. 7:e000377

23. Munroe ME, Lu R, Zhao YD, et al. 2016. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann. Rheum. Dis. 75:2014–21

24. Li QZ, Zhou J, Lian Y, et al. 2010. Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes. Clin. Exp. Immunol. 159:281–91

25. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019. 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis. 78:736–45

26. Dima A, Jurcut C, Chasset F, et al. 2022. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther. Adv.Musculoskelet. Dis. 14:1759720X211073001

27. Almeida-Brasil CC, Hanly JG, Urowitz M, et al. 2022. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus InternationalCollaborating Clinics (SLICC) inception cohort. Ann. Rheumat. Dis. 81:370–78

28. Shinjo SK, Bonfá E,WojdylaD, et al. 2010. Antimalarial treatmentmay have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum. 62:855–62

29. Petri M, Konig MF, Li J, Goldman DW. 2021. Association of higher hydroxychloroquine blood levels with reduced thrombosis risk in systemic lupus erythematosus. Arthritis Rheumatol. 73:997–1004

30. Shipman WD,Vernice NA,DemetresM, Jorizzo JL. 2020. An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: a systematic review. J. Am. Acad. Dermatol. 82:709–22

31. Lambers WM, Westra J, Bootsma H, de Leeuw K. 2021. Hydroxychloroquine suppresses interferoninducible genes and B cell activating factor in patients with incomplete and new-onset systemic lupus erythematosus. J. Rheumatol. 48:847–51

32. Olsen NJ, McAloose C, Carter J, et al. 2016. Clinical and immunologic profiles in incomplete lupus erythematosus and improvement with hydroxychloroquine treatment. Autoimmune Dis. 2016:8791629

33. Balevic SJ, Weiner D, Clowse MEB, et al. 2022. Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes. Lupus Sci.Med. 9:e000602

34. Izmirly P,Kim M,Friedman DM,et al. 2020. Hydroxychloroquine to prevent recurrent congenital heart block in fetuses of anti-SSA/Ro-positive mothers. J. Am. Coll. Cardiol. 76:292–302 348 Lazar • Kahlenberg Annu. Rev

35. Rosenbaum JT, Costenbader KH, Desmarais J, et al. 2021. American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 joint statement on hydroxychloroquine use with respect to retinal toxicity. Arthritis Rheumatol. 73:908–11

36. Petri M, Elkhalifa M, Li J, et al. 2020. Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy. Arthritis Rheumatol. 72:448–53

37. Illei GG, Austin HA, Crane M, et al. 2001. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann. Intern.Med. 135:248–57

38. Ugarte-GilMF, Mak A, Leong J, et al. 2021. Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Sci.Med. 8:e000590

39. Apostolopoulos D, Kandane-Rathnayake R, Louthrenoo W, et al. 2020. Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study. Lancet Rheumatol. 2:e24–e30

40. Borucki R, Werth VP. 2020. Expert perspective: an evidence-based approach to refractory cutaneous lupus erythematosus. Arthritis Rheumatol. 72:1777–85

41. Sakthiswary R, Suresh E. 2014. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus 23:225–35

42. Carrión-Barberà I, Polino L,Mejía-Torres M, et al. 2022. Leflunomide: a safe and effective alternative in systemic lupus erythematosus. Autoimmun. Rev. 21:102960

43. Olivieri G, Ceccarelli F, Natalucci F, et al. 2021. Five-years drug survival of mycophenolate mofetil therapy in patients with systemic lupus erythematosus: comparison between renal and non-renal involvement. Joint Bone Spine 88:105246

44. McCune WJ, Golbus J, Zeldes W, et al. 1988. Clinical and immunologic effects of monthly Administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N. Engl. J. Med. 318:1423–31

45. Houssiau FA, Vasconcelos C, D’Cruz D, et al. 2002. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 46:2121–31

46. Askanase AD, Byron M, Keyes-Elstein LL, et al. (ACCESS Trial Group). 2014. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol. 66:3096–104

47. Appel GB, Contreras G, Dooley MA, et al. 2009. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20:1103–12

48. Furie R, Rovin BH, Houssiau F, et al. 2020. Two-year, randomized, controlled trial of belimumab in lupus nephritis.N. Engl. J. Med. 383:1117–28

49. Park DJ, Kang JH, Lee KE, et al. 2019. Efficacy and safety of mycophenolate mofetil and tacrolimus combination therapy in patients with lupus nephritis: a nationwide multicentre study. Clin. Exp. Rheumatol. 37:89–96

50. Rovin BH, Teng YKO, Ginzler EM, et al. 2021. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised,multicentre, placebo-controlled, phase 3 trial. Lancet 397:2070–80